Literature DB >> 9654401

In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation.

E J Giamarellos-Bourboulis1, P Grecka, A Dionyssiou-Asteriou, H Giamarellou.   

Abstract

Based on previous findings that gamma-linolenic acid (GLA) inhibits Escherichia coli growth and provokes the induction of strains resistant to aminoglycosides, 19 Pseudomonas aeruginosa strains were exposed in vitro over time to GLA, to arachidonic acid (AA) and to their combination in the presence or absence of vitamin E. All acids were used at a 300 microg/ml concentration, whereas vitamin E was added as an antioxidant. Lipid peroxidation was evaluated by the thiobarbiturate assay measuring malonodialdehyde (MDA) production. It was found that GLA or AA killed 5-10% of strains at 24 h of growth, whereas when applied in combination their effect involved 100% of strains at 24 h and was limited to 68% of strains in the presence of vitamin E (P< 0.01). MDA production was time-dependent and it was restrained by vitamin E (P < 0.01). Post acid exposure, 27% to 37% of the survived strains became resistant to diverse antimicrobial agents and mainly to ticarcillin, to ceftazidime and to amikacin; no strain developed resistance in the presence of vitamin E. It is concluded that GLA and AA interact bactericidally on P. aeruginosa isolates, inducing the development of strains resistant to beta-lactams and to aminoglycosides; their action might be mediated through their peroxides. Further research is necessary to establish the clinical application of these in vitro findings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9654401     DOI: 10.1016/s0952-3278(98)90037-0

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  6 in total

1.  In vitro interactions of gamma-linolenic acid and arachidonic acid with ceftazidime on multiresistant Pseudomonas aeruginosa.

Authors:  E J Giamarellos-Bourboulis; P Grecka; A Dionyssiou-Asteriou; H Giamarellou
Journal:  Lipids       Date:  1999       Impact factor: 1.880

2.  Impact of n-6 polyunsaturated fatty acids on growth of multidrug-resistant Pseudomonas aeruginosa: interactions with amikacin and ceftazidime.

Authors:  E J Giamarellos-Bourboulis; P Grecka; A Dionyssiou-Asteriou; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.

Authors:  Evangelos J Giamarellos-Bourboulis; Maria Mouktaroudi; Theodoros Adamis; Vassilios Koussoulas; Fotini Baziaka; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Authors:  Evangelos J Giamarellos-Bourboulis; Theodoros Adamis; George Laoutaris; Lambros Sabracos; Vassilios Koussoulas; Maria Mouktaroudi; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

5.  Pseudomonas aeruginosa responds to exogenous polyunsaturated fatty acids (PUFAs) by modifying phospholipid composition, membrane permeability, and phenotypes associated with virulence.

Authors:  Lyssa Y Baker; Chelsea R Hobby; Andrew W Siv; William C Bible; Michael S Glennon; Derek M Anderson; Steven J Symes; David K Giles
Journal:  BMC Microbiol       Date:  2018-09-14       Impact factor: 3.605

6.  The effects of dexmedetomidine on secondary acute lung and kidney injuries in the rat model of intra-abdominal sepsis.

Authors:  Uğur Koca; Çimen Gülben Olguner; Bekir Uğur Ergür; Emel Altekin; Aydın Taşdöğen; Seden Duru; Pelin Girgin; Kerim Gündüz; Serap Cilaker Mıcılı; Seda Güzeldağ; Muhammed Akkuş
Journal:  ScientificWorldJournal       Date:  2013-02-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.